The efficacy and safety of pazopanib as a second-line treatment for patients with paclitaxel-pretreated primary cutaneous angiosarcoma – results of JCOG1605 study
Cumulative incidence of the most frequent TEAEs in the first 24 months.A plateau effect can be seen after the first 5-10 months Conclusions:The Italian interim analysis of NISSO shows, under real-world conditions, a better safety profile than could be expected based on previous results of the pivotal trial with sonidegib (BOLT).Most patients experienced the onset of common AEs after 3 months of treatment.All the above supports the use of sonidegib as a manageable first-line systemic treatment in patients with laBCC with a favorable impact on patient compliance.
Authors
- Hiroshi Uchi (ORCID: https://orcid.org/0000-0003-2526-3504)
- Shinichiro Mori (ORCID: https://orcid.org/0000-0002-0412-4399)
- Taro Funakoshi (ORCID: https://orcid.org/0000-0002-2355-9216)
- Yuki Shibayama (ORCID: https://orcid.org/0000-0001-9318-7801)
- Yukiko Kiniwa (ORCID: https://orcid.org/0000-0003-3757-7375)
- Naohito Hatta (ORCID: https://orcid.org/0000-0003-1590-8348)
- Yusuke Sano (ORCID: https://orcid.org/0000-0001-6738-1854)
- Takuya Miyagawa (ORCID: https://orcid.org/0000-0002-4471-1635)
- Kohei Oashi (ORCID: https://orcid.org/0000-0002-0123-9430)
- Azusa Hiura
- Takahiko TAKENOUCHI
- Akiko Maruyama (ORCID: https://orcid.org/0000-0002-3240-2843)
- Taku Maeda (ORCID: https://orcid.org/0000-0003-3612-8201)
- Eiji Nakano (ORCID: https://orcid.org/0000-0001-7632-8182)
- Kunihiko Yoshino (ORCID: https://orcid.org/0000-0001-5846-5132)
- N. Yamazaki
- Jiro Uehara (ORCID: https://orcid.org/0000-0002-6656-8905)
- K. Namikawa
- Dai Ogata (ORCID: https://orcid.org/0000-0002-1335-7100)
- Tomoe Nakagawa (ORCID: https://orcid.org/0000-0003-4492-9869)
- Ikko Muto (ORCID: https://orcid.org/0000-0003-4954-5290)
- H. Fukuda
- Masayuki Yokoyama (ORCID: https://orcid.org/0000-0001-6053-1856)
- Atsushi Takahashi (ORCID: https://orcid.org/0000-0003-3340-432X)
- Y Nakamura
Institutions
- Kurume University (JP)
- Shinshu University (JP)
- Asahikawa Medical University (JP)
- Kyoto Prefectural University (JP)
- Keio University (JP)
- Hokkaido University (JP)
- Tokyo Metropolitan Komagome Hospital (JP)
- Fukuoka University (JP)
- Kyoto Prefectural University of Medicine (JP)
- Toyama Prefectural Central Hospital (JP)
- Niigata Cancer Center Hospital (JP)
- National Hospital Organization Kyushu Cancer Center (JP)
- Kurume University Hospital (JP)
- Saitama Cancer Center (JP)
- Saitama International Medical Center (JP)
- National Cancer Center Hospital East (JP)
- Saiseikai Fukuoka General Hospital (JP)
- Japan Clinical Cancer Research Organization (JP)
- Japanese Foundation For Cancer Research (JP)
- Nagoya University (JP)
- The University of Tokyo (JP)
- Saitama Medical University (JP)
- Teikyo University (JP)
Publication Details
- Journal
- EJC Skin Cancer
- Published
- 2025-01-01
- DOI
- https://doi.org/10.1016/j.ejcskn.2025.100337
- Primary Topic
- Vascular Tumors and Angiosarcomas
- Type
- article
- Field-Weighted Citation Impact
- 0.00